Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Gold Price Monitor -- Ignore unavailable to you. Want to Upgrade?

To: Square_Dealings who wrote (84702)	4/24/2002 7:04:47 AM
From: long-gone	Respond to of 116753

This should be noted: AngloGold’s Response to HIV/AIDS Report Released for 2001/2002 Date: Wednesday, April 24, 2002 AngloGold today releases its HIV/AIDS report for 2001/2002, which details the company’s comprehensive response to AIDS in the workplace. AngloGold’s HIV/AIDS programme is focused on three key areas: - Prevention management Restricting the spread of HIV/AIDS through education, the promotion of condom use and the effective treatment of sexually transmitted infections. - Caring for those infected Through voluntary counselling and testing, wellness clinics, the treatment of opportunistic infections and a compassionate ill health retirement system for those no longer able to work. - Health research Conducting fundamental research to inform the company’s management of occupational health, including TB and HIV/AIDS. Findings can be quickly and effectively implemented into the workplace, shortening the traditional gap between research and implementation. AngloGold’s own research, using data gathered from sexually transmitted infection clinics in 2001, indicates HIV prevalence levels of between 25 - 30% amongst the company’s 44,000 South African employees, depending on the location of the operation, which reflects levels similar to the range of prevalence of the virus throughout South Africa. Bobby Godsell, Chairman and CEO, explains the company’s position “Two responses to HIV/AIDS are clearly wrong and unhelpful: the first is to deny the magnitude of the challenge AIDS poses to South Africa; and the second is to be defeatist and engage in apocalyptic predictions of disaster. “While HIV/AIDS is a human tragedy of grave proportions, its impact on AngloGold can be managed and contained. We estimate that HIV/AIDS is currently increasing costs in the South African operations by between US$4and US$6/oz, though there are reasonable prospects of reducing this with the range of activities that we have in place. We are convinced that the combination of education, compassionate care and the rigorous scientific search for medical responses to the virus will reap rewards for our employees, their families and communities, and, in turn, the company and its shareholders.” Commenting on the company’s research programme, Dr Colin Eisenstein, Managing Director: Anglogold Health Services and Medical Consultant at AngloGold, said “Our world class research institution, Aurum Health Research, has developed highly effective responses to tuberculosis and other diseases associated with the virus and is actively involved in the search for an HIV/AIDS vaccine. “With respect to Highly Active Anti-retroviral Therapy (HAART), the challenge that we face in South Africa is to develop an approach to this form of treatment which takes into account the realities of this industry and region. We are committed to developing a collaborative research programme with the rest of the industry and with Government which will identify the appropriate application of HAART in our circumstances.” Disclaimer Except for the historical information which may be contained herein, there maybe matters discussed in this news release that are forward-looking statements. Such statements are only predictions and actual events or results may differ materially. For a discussion of important factors including, but not limited to, development of the Company's business, the economic outlook in the gold mining industry, expectations regarding gold prices and production, and other factors, which could cause actual results to differ materially from such forward-looking statements, refer to the Company's annual report on the Form 20-F for the year ended December 31, 2000 which was filed with the Securities and Exchange Commission on April 23, 2001. anglogold.co.za